Metastatic Hormone refractory prostate cancer recent advances in standard treatment paradigm, and future directions

American Journal of Clinical Oncology: Cancer Clinical Trials

Volumn 37, Issue 3, 2014, Pages 289-296

  Keizman, Daniel ^a   Maimon, Natalie ^a   Gottfried, Maya ^a  

^a TEL AVIV UNIVERSITY   (Israel)

Author keywords

Metastatic hormone refractory prostate cancer; Recent advances; Standard treatments

Indexed keywords

ABIRATERONE; ANTIANDROGEN; ANTINEOPLASTIC AGENT; ATRASENTAN; BEVACIZUMAB; BISPHOSPHONIC ACID DERIVATIVE; CABAZITAXEL; CABOZANTINIB; CATHEPSIN K INHIBITOR; DASATINIB; DENOSUMAB; DOCETAXEL; LENALIDOMIDE; OSTEOCLAST DIFFERENTIATION FACTOR; RADIUM CHLORIDE RA 223; SARACATINIB; SIPULEUCEL T; TASQUINIMOD; ZIBOTENTAN; ANDROSTANE DERIVATIVE; ANGIOGENESIS INHIBITOR; CANCER VACCINE; CATHEPSIN K; ENDOTHELIN RECEPTOR; PROTEIN TYROSINE KINASE; RADIOPHARMACEUTICAL AGENT; TAXOID; TISSUE EXTRACT; VASCULOTROPIN RECEPTOR;

ANTIANGIOGENIC ACTIVITY; ANTINEOPLASTIC ACTIVITY; ANTIPROLIFERATIVE ACTIVITY; BONE METASTASIS; CANCER CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CASTRATION RESISTANT PROSTATE CANCER; CLINICAL TRIAL (TOPIC); EXTERNAL BEAM RADIOTHERAPY; HORMONAL THERAPY; HUMAN; IMMUNOMODULATION; MALE; MOLECULAR PATHOLOGY; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; DENDRITIC CELL; DRUG ANTAGONISM; DRUG EFFECT; IMMUNOLOGY; METABOLISM; METHODOLOGY; MOLECULARLY TARGETED THERAPY; MORTALITY; PATHOLOGY; PROSTATE TUMOR; SIGNAL TRANSDUCTION;

ANDROGEN ANTAGONISTS; ANDROSTENOLS; ANGIOGENESIS INHIBITORS; ANTINEOPLASTIC AGENTS; CANCER VACCINES; CATHEPSIN K; DENDRITIC CELLS; HUMANS; MALE; MOLECULAR TARGETED THERAPY; PROSTATIC NEOPLASMS; RADIOPHARMACEUTICALS; RANK LIGAND; RECEPTORS, ENDOTHELIN; RECEPTORS, VASCULAR ENDOTHELIAL GROWTH FACTOR; SIGNAL TRANSDUCTION; SRC-FAMILY KINASES; TAXOIDS; TISSUE EXTRACTS;

EID: 84908028642     PISSN: 02773732     EISSN: 1537453X     Source Type: Journal    
DOI: 10.1097/COC.0b013e318248dc1e     Document Type: Review

References (40)

1. Jemal A, Siegel R, Xu J, et al. Cancer statistics, 2010. CA Cancer J Clin. 2010;60:277-300.
2. Loblaw DA, Virgo KS, Nam R, et al. Initial hormonal management of androgen-sensitive metastatic, recurrent, or progressive prostate cancer: 2006 update of an American Society of Clinical Oncology practice guideline. J Clin Oncol. 2007;25: 1596-1605.
3. Eisenberger MA, Blumenstein BA, Crawford ED, et al. Bilateral orchiectomy with or without flutamide for metastatic prostate cancer. N Engl J Med. 1998;339:1036-1042.
4. Keizman D, Huang P, Carducci MA, et al. Contemporary experience with ketoconazole in patients with metastatic castration resistant prostate cancer: clinical factors associated with PSA response and disease progression. Prostate. 2012;72:461-467.
5. Taplin ME, Rajeshkumar B, Halabi S, et al. Androgen receptor mutations in androgen-independent prostate cancer: Cancer and Leukemia Group B Study 9663. J Clin Oncol. 2003;21: 2673-2678.
6. July LV, Akbari M, Zellweger T, et al. Clusterin expression is significantly enhanced in prostate cancer cells following androgen withdrawal therapy. Prostate. 2002;50:179-188.
7. Craft N, Shostak Y, Carey M, et al. A mechanism for hormoneindependent prostate cancer through modulation of androgen receptor signaling by the HER-2/neu tyrosine kinase. Nat Med. 1999;5:280-285.
8. Kantoff PW, Higano CS, Shore ND, et al. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med. 2010;363:411-422.
9. Petrylak DP, Tangen CM, Hussain MH, et al. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med. 2004;351: 1513-1520.
10. Tannock IF, de Wit R, Berry WR, et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med. 2004;351:1502-1512.
11. de Bono JS, Logothetis CJ, Molina A, et al. Abiraterone and increased survival in metastatic prostate cancer. N Engl J Med. 2011;364:1995-2005.
12. de Bono JS, Oudard S, Ozguroglu M, et al. Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: A randomized open-label trial. Lancet. 2010;376:1147-1154.
13. Saad F, Gleason DM, Murray R, et al. A randomized, placebocontrolled trial of zoledronic acid in patients with hormonerefractory metastatic prostate carcinoma. J Natl Cancer Inst. 2002;94:1458-1468.
14. Smith MR, Egerdie B, Hernández Toriz N, et al. Denosumab in men receiving androgen-deprivation therapy for prostate cancer. N Engl J Med. 2009;361:745-755.
15. Fizazi K, Carducci M, Smith M, et al. Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: A randomised, doubleblind study. Lancet. 2011;377:813-822.
16. Scher HI, Beer TM, Higano CS, et al. Antitumour activity of MDV3100 in castration-resistant prostate cancer: A phase 1-2 study. Lancet. 2010;375:1437-1446.
17. Keizman D, Zahurak M, Sinibaldi V, et al. Lenalidomide in nonmetastatic biochemically relapsed prostate cancer: results of a phase I/II double-blinded, randomized study. Clin Cancer Res. 2010;16:5269-5276.
18. Kelly WK, Halabi S, Carducci MA, et al. A randomized, doubleblind, placebo-controlled phase III trial comparing docetaxel, prednisone, and placebo with docetaxel, prednisone, and bevacizumab in men with metastatic castration-resistant prostate cancer (mCRPC): Survival results of CALGB 90401. J Clin Oncol. 2010;28:18s. (suppl; abstrLBA4511).
19. Pili R, Haggman M, Stadler WM, et al. A randomized, multicenter, international phase II study of tasquinimod in chemotherapy naive patients with metastatic castrate resistant prostate cancer (CRPC) (abstract #4510). J Clin Oncol. 2010;28:344s.
20. Carducci MA, Jimeno A. Targeting bone metastasis in prostate cancer with endothelin receptor antagonists. Clin Cancer Res. 2006;12:6296s-6300s. Review.
21. Carducci MA, Saad F, Abrahamsson PA, et al. A phase 3 randomized controlled trial of the efficacy and safety of atrasentan in men with metastatic hormone-refractory prostate cancer. Cancer. 2007;110:1959-1966.
22. Nelson JB, Love W, Chin JL, et al. Phase 3, randomized, controlled trial of atrasentan in patients with nonmetastatic, hormone-refractory prostate cancer. Cancer. 2008;113:2478-2487.
23. James ND, Caty A, Payne H, et al. Final safety and efficacy analysis of the specific endothelin A receptor antagonist zibotentan (ZD4054) in patients with metastatic castration resistant prostate cancer and bone metastases who were pain-free or mildly symptomatic for pain: A double-blind, placebocontrolled, randomized Phase II trial. BJU Int. 2010;106:966-973.
24. Nelson JB, Fizazi K, Miller K, et al. Phase III study of the efficacy and safety of zibotentan (ZD4054) in patients with bone metastatic castration-resistant prostate cancer (CRPC). J Clin Oncol. 2011; 29(suppl 7): Abstract117 (ASCO, Genitourinary cancer symposium, 2011).
25. Scher HI, Halabi S, Tannock I, et al. Design and endpoints of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group. J Clin Oncol. 2008;26:1148-1159.
26. Edwards J. Src kinase inhibitors: An emerging therapeutic treatment option for prostate cancer. Expert Opin Investig Drugs. 2010;19:605-614.
27. Fizazi K. The role of Src in prostate cancer. Ann Oncol. 2007; 18:1765-1773.
28. Yu EY, Wilding G, Posadas E, et al. Phase II study of dasatinib in patients with metastatic castration-resistant prostate cancer. Clin Cancer Res. 2009;15:7421-7428.
29. Yu EY, Massard C, Gross ME, et al. Once daily dasatinib: expansion of a phase 2 study evaluating the safety and efficacy of dastanib in patients with metastatic castration resistant prostate cancer. Urology. 2011;77:1166-1171.
30. Araujo J, Gallick G, Trudel G, et al. Dasatinib and docetaxel combination treatment for patients with castration resistant progressive prostate cancer: A phase 1/2 study (CA180-086). J Clin Oncol. 2009;27:15s. (abstract5061).
31. Lara PN Jr, Longmate J, Evans CP, et al. A phase II trial of the Src-kinase inhibitor AZD0530 in patients with advanced castration-resistant prostate cancer: A California Cancer Consortium study. Anticancer Drugs. 2009;20:179-184.
32. Hussain M, Smith MR, Sweeney C, et al. Cabozantinib (XL184) in metastatic castration-resistant prostate cancer: Results from a phase II randomized discontinuation trial (abstract #4516). J Clin Oncol. 2011;29:293s.
33. Porter AT, McEwan AJ, Powe JE, et al. Results of a randomized phase-III trial to evaluate the efficacy of strontium-89 adjuvant to local field external beam irradiation in the management of endocrine resistant metastatic prostate cancer. Int J Radiat Oncol Biol Phys. 1993;25:805-813.
34. Sartor O, Reid RH, Hoskin PJ, et al. Samarium-153-Lexidronam complex for treatment of painful bone metastases in hormone-refractory prostate cancer. Urology. 2004;63: 940-945.
35. Nilsson S, Larsen RH, Fossa SD, et al. First clinical experience with A-emitting Radium-223 in the treatment of skeletal metastases. Clin Cancer Res. 2005;11:4451-4459.
36. Nilsson S, Franzen L, Tyrrell C, et al. Bone-seeking radium-223 adjuvant to external beam radiotherapy demonstrates significant decline in bone-alkaline phosphatase and PSA in patients with hormone refractory prostate cancer. ASCO Prostate Cancer Symposium. 2006. (abstract 215).
37. Parker C, O'Bryan-Tear CG, Bolstad B, et al. Alkaline phosphatase (ALP) normalization and overall survival in patients with bone metastasis from castration-resistant prostate cancer (CRPC) treated with radium-223. ASCO Genitourinary Cancer Symposium. 2011;29(suppl 15):4620(abstract).
38. Parker C, Heinrich D, O'Sullivan JM, et al. Overall survival benefit of radium-223 chloride (Alpharadin) in the treatment of patients with symptomatic bone metastases in castration-resistant prostate cancer: A phase III randomized trial (ALSYMPCA). Eur J Cancer. 2011;47(suppl 2):3, (Abstract1LBA).
39. Podgorski I, Linebaugh BE, Koblinski JE, et al. Bone marrow derived cathepsin K cleaves SPARC in bone metastasis. Am J Pathol. 2009;175:1255-1269.
40. Jensen AB, Wynne C, Ramirez G, et al. The cathepsin K inhibitor odanacatib suppresses bone resorption in women with breast cancer and established bone metastases: results of a 4-week, double-blind, randomized, controlled trial. Clin Breast Cancer. 2010;10:452-458.